Anti‐leukotrienes & ICS may leads to higher participants with exacerbations requiring hospital admission compared with higher dose ICS (low certainty).
Intermittent 'as needed' ICS showed no clear difference in patients with serious adverse health events (duration 12 to 52 weeks) compared with daily ICS (low certainty).
Intermittent 'as needed' ICS showed no clear difference in patients with at least 1 exacerbation requiring emergency… compared with daily ICS (low certainty).
Intermittent 'as needed' ICS showed no clear difference in change from baseline AM PEFR (%) (duration 44 to 52 weeks) compared with daily ICS (moderate certainty).
Intermittent 'as needed' ICS showed no clear difference in proportion of asthma control days over the period (duration 44 to 52… compared with daily ICS (moderate certainty).
Intermittent 'as needed' ICS showed no clear difference in change from baseline mean daily use of β2‐agonists (puffs/day)… compared with daily ICS (moderate certainty).
Intermittent 'as needed' ICS probably leads to higher change in height (cm) (duration 44 to 52 weeks) compared with daily ICS (moderate certainty).
Intermittent 'as needed' ICS showed no clear difference in overall withdrawals (duration 12 to 52 weeks) compared with daily ICS (low certainty).
It is very uncertain whether ciclesonide changes patients with exacerbations Number of patients with exacerbations compared with budesonide (dose ratio 1:2) (very low certainty).
It is very uncertain whether ciclesonide changes patients with exacerbations Number of patients with exacerbations compared with fluticasone (dose ratio 1:1) (very low certainty).
It is very uncertain whether ciclesonide changes patients with exacerbations Number of patients with exacerbations compared with fluticasone (dose ratio 1:2) (very low certainty).
It is very uncertain whether ciclesonide changes adverse events Number of patients with adverse events compared with fluticasone (dose ratio 1:2) (very low certainty).
ICS may leads to lower hospital admission compared with placebo (low certainty).
ICS showed no clear difference in FEV1 at 1 hour compared with placebo (low certainty).
ICS showed no clear difference in FEV1 at 3 to 4 hours compared with placebo (moderate certainty).